Mangalam Drugs & Organics (NSE:MANGALAM) Total Equity: ₹1,031 Mil (As of Mar. 2026)


NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
43 GF Score
Price ₹28.25
GF Value ₹63.10
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics Total Equity?

Mangalam Drugs & Organics NSE:MANGALAM -0.67% 43 Total Equity is ₹1,031 Mil as of Mar. 2026. GuruFocus rates NSE:MANGALAM with a GF Score™ of 43/100 and a GF Value™ of ₹63.10 (Possible Value Trap). The stock has 4 warning signs investors should review.

Mangalam Drugs & Organics's total equity for the quarter that ended in Mar. 2026 was ₹1,031 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Mangalam Drugs & Organics Total Equity Historical Data

* Premium members only.

The historical data trend for Mangalam Drugs & Organics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mangalam Drugs & Organics Total Equity Chart

Mangalam Drugs & Organics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,505.61 1,519.56 1,357.93 1,489.79 1,030.59

Mangalam Drugs & Organics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,489.79 0.00 1,275.75 0.00 1,030.59
NSE:MANGALAM
43GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mangalam Drugs & Organics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Mangalam Drugs & Organics's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3149.693-2119.103
=1,031

Mangalam Drugs & Organics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3149.693-2119.103
=1,031

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹1,031 Mil mean?
Mangalam Drugs & Organics (NSE:MANGALAM) has a Total Equity of ₹1,031 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Mangalam Drugs & Organics and its competitors.
Is Mangalam Drugs & Organics' Total Equity too high?
Mangalam Drugs & Organics' current Total Equity is ₹1,031 Mil. Overall, Mangalam Drugs & Organics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Total Equity compare to ZTS and UTHR?
Mangalam Drugs & Organics' Total Equity of ₹1,031 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Mangalam Drugs & Organics and its competitors. Mangalam Drugs & Organics's current Total Equity is ₹1,031 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹63.10, compared to a current price of ₹28.25 — trading 55.2% below its estimated fair value. The current Total Equity is ₹1,031 Mil. Mangalam Drugs & Organics' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Total Equity is ₹1,031 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹28.25 is trading 55.2% below its estimated GF Value™ of ₹63.10. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • Total Equity: ₹1,031 Mil
  • GF Value™: ₹63.10 vs. price of ₹28.25 (55.2% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
43GF Score

Get the complete analysis for NSE:MANGALAM

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹28.25
Price
₹63.10
GF Value